Detall de la convocatòria
Característiques
Característica |
---|
Objectiu de la convocatòria
The Alzheimer's Drug Discovery Foundation (ADDF) funds drug discovery and development research programs in the field of Alzheimer's disease (AD), related dementias and cognitive aging. The ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising drug discovery and development programs. In addition to funding academic programs, the ADDF also invests in and creates early stage biotechnology companies. The ADDF also co-sponsors conferences to stimulate new ideas and approaches in areas of interest to the Foundation. |
Característiques principals
Research investigating the pathogenic mechanisms underlying frontotemporal degeneration (FTD) is advancing, creating new targets for drug discovery. However, there remains a global gap in FTD drug discovery research. The Alzheimer's Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy) drug discovery programs for FTD through this request for proposals (RFP). Priority areas for this program include: |
Lloc de presentació
El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a: Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76. Marta López: mlopez4@imim.es Ext.: 1576 Carol Barnwell: cbarnwell@imim.es Ext.: 1670 |
Convocatòria (URL)
https://www.alzdiscovery.org/research-and-grants/funding-opportunities/accelerating-drug-discovery-for-ftd Applications: https://addf.fluxx.io/user_sessions/new |
Dotació
Budgets averaging $100,000-$150,000 are recommended. |
Durada
Average duration: 1 year |
AVÍS IMPORTANT
The deadline for applications is August 10, 2018. Submission of a Letter of Intent (LOI) is required on or before July 13, 2018. LOIs are reviewed on a rolling basis and can be submitted any time prior to the deadline. |